Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07602205

Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A PROBE Clinical Trial

The primary objective of this research is to study the efficacy and safety of daily, home-based hyperthermic baths for reducing epileptic seizures in CDKL5 Deficiency Disorder.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This is a prospective, randomized, open-label, blinded-endpoint study designed to evaluate the efficacy and safety of daily home-based hyperthermic bathing in participants with CDKL5 deficiency disorder. Eligible participants will be randomized in a 1:1 ratio to receive either hyperthermic baths in addition to usual antiseizure care or usual antiseizure care alone without hyperthermic baths. Efficacy will be assessed primarily by changes in epileptic seizure burden, and safety will be evaluated throughout the study period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A diagnosis of CDKL5 deficiency disorder, including molecular confirmation of a pathogenic CDKL5 variant and exhibiting epileptic seizures.
  • Male or female participants aged 6 months to 14 years, inclusive.
  • Patients presenting with drug-resistant epilepsy that seizures were uncontrolled despite the appropriate trial of at least two antiseizure medications (ASMs).
  • At least 8 motor seizures during each 4 weeks in the 8-week historical seizure records preceding screening.
  • Treatment regimens of 0-4 ASMs were required to be stable for at least 4 weeks before screening and throughout the intervention. Ongoing ketogenic diets were allowed if remain unchanged during screening and treatment.
  • Subjects who have undergone surgical implantation of vagus nerve stimulation (VNS) will be eligible for inclusion in the study, provided they meet all of the following criteria:
  • The VNS device has been in place for at least one year prior to the screening visit;
  • The stimulation parameters remain unchanged throughout the duration of the trial.
  • Parents or caregivers must be able and willing to maintain an accurate and comprehensive daily electronic seizure diary throughout the duration of the study.
  • Participants' legal guardians willing to provide written informed consent.

Exclusion criteria

  • Patients who had any history of previous brain disease (including trauma, encephalitis, etc.) that were likely to precipitate seizures; defined by MRI outcomes.
  • Participants with skin ulceration or dermatologic conditions that make bathing unsuitable.
  • Parents or guardians who, based on past experiences, determine that the child has an intolerance to thermal baths.
  • A history of seizures induced by thermal baths, or an increase in seizure frequency after thermal baths.
  • Patients who presented any clinical condition that in the opinion of the principal investigator made the patient not suitable to participate in the survey.

Treatment and study plan

Home-based hyperthermic Baths

Behavioral

A 12-week daily home-based hyperthermic bathing intervention consisting of immersion in a 40-42°C water bath for 20 minutes per session under continuous parental supervision. The intervention will be administered according to the study protocol.

Primary outcomes

  1. Seizure Responder Rate

    Time frame: Baseline to week 12 at home-based hyperthermic baths phase

    The proportion of participants achieving at least a 50% reduction in seizure frequency from baseline during the 12-week home-based hyperthermic baths period.

Secondary outcomes

  1. Change in Seizure Frequency

    Time frame: Baseline to week 12 at home-based hyperthermic baths phase

    Change in the frequency of epileptic seizures from baseline to the 12-week home-based hyperthermic baths period.

  2. Seizure-free Days

    Time frame: Baseline to week 12 at home-based hyperthermic baths phase

    Number of days without epileptic seizures during the 12-week treatment period.

Study contacts

Contact information is provided by the study sponsor or research team.

Liankun Ren, MD, PhD

CONTACT

[email protected]

+86 13681576621

Sponsors and collaborators

Lead sponsor

Xuanwu Hospital, Beijing

Other

Registry information

Official study title

Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A Prospective, Randomized, Parallel-Controlled, Open-Label, Blinded Endpoint (PROBE) Clinical Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 22, 2026
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.